Comparative clinical study of alilocumab (Praluent) and evorocumab (Repatha) for dyslipidemia

Comparative clinical study of alilocumab (Praluent) and evorocumab (Repatha) for dyslipidemia - Alilocumab and evorocumab for dyslipidemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034592

Enrollment

Registered

2018-10-26

Start date

2018-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia using evolocumab

Interventions

Alilocumab group: 75mgx2/month for one year Evolocumab group: 140mgx2/month for one year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Dyslipidemia using evolocumab

Exclusion criteria

Exclusion criteria: Patients who were deemed not appropriate to participate in this study by doctor

Design outcomes

Primary

Measure	Time frame
LDL, HDL, T-cho, TG	—

Secondary

Measure	Time frame
1) BUN, Cr, AST, ALT, CK, HbA1c 2) U-Alb, cystatin C, oxidized LDL, fatty acid fractionation, Lipo (a), Lipo fractionation, remnant-Like Particle 3) FMD, carotid echo, ABI 4) PCSK9 concentration 5) Cardiovascular events	—

Countries

Japan

Contacts

Public ContactMitsue Akiyama

Sekino Laboratory Department of Research

skn-np@sekino-hospital.com03-3986-5501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026